Acasti Pharma Inc.

0.9000+0.0120+1.35%Vol 119.93K1Y Perf -75.38%
Aug 11th, 2022 16:00 DELAYED
BID0.8850 ASK0.9200
Open0.8800 Previous Close0.8880
Pre-Market- After-Market0.89
 - -  -0.01 -1.33%
Target Price
6.37 
Analyst Rating
Strong Buy 1.00
Potential %
607.78 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★★★     63.14
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
+ —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
3.23 
Earnings Rating
Buy
Market Cap40.04M 
Earnings Date
11th Aug 2022
Alpha-0.00 Standard Deviation0.36
Beta1.78 

Today's Price Range

0.87120.9254

52W Range

0.80003.89

5 Year PE Ratio Range

-2.90-3.00

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Buy
Performance
1 Week
4.04%
1 Month
3.46%
3 Months
5.87%
6 Months
-21.05%
1 Year
-75.38%
3 Years
-94.23%
5 Years
-91.54%
10 Years
-99.48%

TickerPriceChg.Chg.%
ACST0.90000.01201.35
AAPL168.49-0.7500-0.44
GOOG119.82-0.8300-0.69
MSFT287.02-2.1400-0.74
XOM93.192.62002.89
WFC45.250.92002.08
JNJ167.14-3.5300-2.07
FB196.640.99000.51
GE78.901.76002.28
JPM120.141.75001.48
 
ProfitabilityValueIndustryS&P 500US Markets
65.20
-18 944.30
-18 943.50
-
-
RevenueValueIndustryS&P 500US Markets
0.00
0.00
-
-
Earnings HistoryEstimateReportedSurprise %
Q04 2022-0.13-0.0469.23
Q03 2022-0.08-0.09-12.50
Q02 2022-0.03-
Q01 2022--0.08-
Q04 2021--0.24-
Q03 2021--0.16-
Q02 2021-0.56-0.4028.57
Q01 2021-0.07-0.0528.57
Earnings Per EndEstimateRevision %Trend
3/2022 QR-0.130.00-
3/2022 QR-0.08--
3/2023 FY-0.6212.68Positive
3/2024 FY-0.5024.24Positive
Next Report Date-
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume119.93K
Shares Outstanding44.49K
Shares Float44.42M
Trades Count565
Dollar Volume108.62K
Avg. Volume85.47K
Avg. Weekly Volume84.26K
Avg. Monthly Volume73.19K
Avg. Quarterly Volume98.96K

Acasti Pharma Inc. (NASDAQ: ACST) stock closed at 0.9 per share at the end of the most recent trading day (a 1.35% change compared to the prior day closing price) with a volume of 119.93K shares and market capitalization of 40.04M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 32 people. Acasti Pharma Inc. CEO is Janelle D'Alvise.

The one-year performance of Acasti Pharma Inc. stock is -75.38%, while year-to-date (YTD) performance is -28.57%. ACST stock has a five-year performance of -91.54%. Its 52-week range is between 0.8 and 3.892, which gives ACST stock a 52-week price range ratio of 3.23%

Acasti Pharma Inc. currently has a PE ratio of -5.10, a price-to-book (PB) ratio of 0.36, a price-to-sale (PS) ratio of 450.58, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -10.47%, a ROC of -12.04% and a ROE of -12.21%. The company’s profit margin is -%, its EBITDA margin is -18 943.50%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Acasti Pharma Inc., there were 1 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Acasti Pharma Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Acasti Pharma Inc. is Strong Buy (1), with a target price of $6.37, which is +607.78% compared to the current price. The earnings rating for Acasti Pharma Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Acasti Pharma Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Acasti Pharma Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 27.17, ATR14 : 0.04, CCI20 : 173.79, Chaikin Money Flow : -0.02, MACD : 0.00, Money Flow Index : 67.42, ROC : 7.14, RSI : 47.63, STOCH (14,3) : 79.74, STOCH RSI : 1.00, UO : 57.59, Williams %R : -20.26), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Acasti Pharma Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
1 (100.00 %)
1 (100.00 %)
1 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Acasti Pharma Inc.

Acasti Pharma Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. Its novel drug delivery technologies have the potential to improve the performance of marketed drugs by achieving faster onset of action, enhanced efficacy, reduced side effects, and more convenient drug delivery all which could help to increase treatment compliance and improve patient outcomes.

CEO: Janelle D'Alvise

Telephone: +1 450 687-2262

Address: 3009 Boulevard de la Concorde East, Laval H7E 2B5, QC, CA

Number of employees: 32

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

68%32%

Bearish Bullish

60%40%

Bearish Bullish

62%38%


News

Stocktwits